Summary & Overview
HCPCS Level II J7199: Hemophilia Clotting Factor, Not Otherwise Classified
HCPCS Level II code J7199 denotes hemophilia clotting factor products that are not otherwise classified under specific HCPCS codes. These agents are used for clotting factor replacement in patients with hemophilia and related coagulation disorders and are administered in outpatient and infusion settings. Nationally, accurate coding for non-classified clotting factors matters for clinical continuity, billing clarity, and payer adjudication given high-cost biologic treatments and utilization oversight.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a succinct overview of coverage considerations across major payers, common modifiers used with this type of HCPCS Level II code, and clinical context for therapeutic use. The publication outlines benchmark cost and utilization topics, policy and reimbursement updates that affect hemophilia factor billing, and operational implications for providers managing billing and claims for non-classified clotting factor products. Data not available in the input for certain fields is noted where applicable.
Billing Code Overview
HCPCS Level II code J7199 is described as Hemophilia clotting factor, not otherwise classified. This code represents injectable clotting factor products used in the treatment of hemophilia when a specific HCPCS code for the product is not available or the product is not otherwise classified.
-
Service Type: Therapeutic clotting factor replacement
-
Typical Site of Service: Hospital outpatient departments, physician offices, infusion centers, and outpatient infusion clinics
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 28-year-old male with severe hemophilia A presents to an infusion center for replacement therapy after experiencing spontaneous hemarthrosis of the right knee. The patient requires clotting factor concentrate that is not specifically listed under standard HCPCS codes (factor not otherwise classified). The medication is supplied by the outpatient infusion pharmacy, documented as J7199 on the claim. Clinical workflow includes verification of weight and recent factor activity level, reconciliation of home factor supply, nursing assessment, infusion of the appropriate dose under physician orders, monitoring for infusion reactions, and documentation of lot number, units administered, start/stop times, and patient response. Prior authorization and medical necessity documentation are obtained when required by the payer; billing includes the J7199 HCPCS Level II code with appropriate modifiers for clinical circumstances and payer-specific requirements. Typical sites of service include hospital outpatient infusion centers, ambulatory infusion clinics, and specialty pharmacies coordinating home infusion services. Typical patient scenarios include congenital hemophilia A or B with inhibitors, acquired hemophilia requiring bypassing agents, or rare factor concentrates not otherwise classified that are administered for episodic bleeding, perioperative prophylaxis, or routine replacement therapy.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 |